Inconsistent Quality System Evidence in Vietnam Medical Device Registration: What Should Manufacturers Do?

When the quality system evidence submitted for medical device registration in Vietnam does not align with the rest of the dossier, the company should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality system, labels and instructions for use, local agent arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete evidence or ambiguous authorisation arrangements do not extend the project timeline.

Published: 10 July 2026, 18:48 | Updated: 10 July 2026, 18:48

This FAQ sets out the questions that companies most need to resolve first in international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Content Structure

• Key points
• Applicable scenarios and core questions
• Registration decision logic
• Documentation and evidence
• Common errors
• Company preparation checklist
• AIMEILI's view
• Frequently followed-up questions
• Further reading
• Applicability boundary

Key Points

On the question of what to do when quality system evidence is inconsistent for medical device registration in Vietnam, companies should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality system, labels and instructions for use, local agent arrangements, clinical evidence and post-market maintenance requirements. AIMEILI recommends a documentation gap assessment before formal submission to avoid project delays caused by unclear classification, incomplete documentation or ambiguous authorisation arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Vietnam registration typically affects the technical file, authorised representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If the project is driven only by asking which documents must be submitted, deficiencies or rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control.

AIMEILI recommends that companies plan this issue within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets, rather than rebuilding documentation from scratch for each country.

Compiled from AIMEILI registration practice records, the medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product's documentation base.

Applicable Scenarios and Core Questions

Companies searching for guidance on inconsistent quality system evidence in Vietnam medical device registration are usually not looking for a conceptual explanation. They want to know whether their existing documentation can support a Vietnam submission, whether a local agent or authorised representative is required, why timelines are being extended, and which issues could affect the launch plan. Behind this question there are usually several linked matters: product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for one country alone is not sufficient. A more valuable approach is to first prepare reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labels and instructions for use, and then adapt them to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use environment, mode of body contact, duration of use, sterility, whether the device is active, and whether it includes software or has IVD characteristics. Only then can the risk class and submission pathway be determined. If the pathway is judged incorrectly, all subsequent translation, notarisation, authorisation, testing and supplementary documentation will move in the wrong direction.

For a Vietnam project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who handles regulatory communication, who manages importation and post-market incidents, who triggers changes and who maintains renewal documentation. If these points are left vague in the commercial contract, market control can be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or other applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and instructions for use, authorisation documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Claims in the instructions for use, the model coverage of test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulatory authorities focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Errors

The most common problem is treating registration as a simple document submission exercise without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly without restructuring the evidence according to the Vietnam pathway.
• An excessive number of models and specifications, with insufficient coverage in test reports, clinical evidence or labels.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibilities, certificate control and post-market maintenance duties.
• Inconsistency between labels, instructions for use, promotional materials and registration claims, leading to deficiency letters or post-market compliance risk.
• Failure to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English instructions for use.
• Confirm the duties, fees, certificate control and exit mechanism of the local agent or authorised representative.
• Establish a gap assessment table for the target country, identifying what must be retested, translated, notarised or supported by additional declarations.

AIMEILI's View

AIMEILI advises companies not to treat Vietnam registration as a one-off document submission, but to manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster and more stable than filling documentation gaps country by country, and it also supports later changes and certificate renewals more effectively.

From a project management perspective, three matters should be controlled early: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three are unclear, the project may still face repeated rounds of deficiency responses, agent communication and post-market maintenance issues, even when the documentation appears extensive.

Frequently Followed-up Questions

Can domestic documentation be used directly for Vietnam registration?

Domestic documentation can serve as a foundation, but it usually cannot be submitted as is. Companies need to adjust the document structure, language, labels, authorisation documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after confirming the target markets and product list. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent usually participates in registration communication, changes, renewals and post-market incident handling. Unclear responsibilities and rights can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project register that manages the product list, model and specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified in good time and helps management judge whether the project will affect the launch plan.

For companies that already hold registrations in several countries, an evidence reuse matrix should also be established, clarifying which documents can serve as core evidence and which must be reissued or supplemented in line with national requirements. Labels and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates must in particular remain version-consistent.

• Confirm target markets and the product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define local agent arrangements and certificate control.
• Track translation, notarisation, testing and deficiency response status.
• Plan post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities generally examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope of an ISO 13485 certificate does not match the products being filed, or if the manufacturing site, model specifications and instruction version do not align with the test reports, a company may be asked for supplementary explanations even if it has prepared a large volume of documentation.

Companies should establish an evidence consistency checklist before submission, mapping product name, model and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instruction version, and quality system certificates item by item. This step appears basic, but it can significantly reduce the likelihood of deficiency letters, particularly for projects involving multiple GHWP member states or several product families submitted at the same time.

Localisation Conversion and Agent Responsibilities

Vietnam registration projects typically involve arrangements with a local agent, authorised representative, importer or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documentation or also handles regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions for use and authorisation documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative details and after-sales contact information. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation conversion is to turn reusable evidence into a submission structure acceptable in the target country, rather than writing a separate, isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is finished. Companies also need to maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining a certificate but neglect post-market maintenance. If a manufacturing site change, model expansion, instruction update or agent replacement later occurs, the certificate can easily become disconnected from actual market sales.

AIMEILI recommends managing this issue within an annual international registration plan: first set market priorities, then build a reusable documentation package and a national gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only improved efficiency in a single country, but also the development of a repeatable compliance capability for going global, reducing the cost of starting from zero each time a new market is entered.

Further Reading

• Previous: How should performance verification documentation be prepared for medical device registration in Vietnam?
• Next: How should registration documentation be prepared for medical device registration in the Philippines?
• Recommended: How should registration documentation be prepared for medical device registration in Malaysia?
• Recommended: How is product classification determined for medical device registration in Malaysia?
• Recommended: How should the technical file be organised for medical device registration in Malaysia?
• Recommended: How should labels and instructions for use be localised for medical device registration in Malaysia?
• Recommended: How should clinical evaluation documentation be prepared for medical device registration in Malaysia?
• Recommended: Can test reports be reused for medical device registration in Malaysia?

Content Review and Applicability Boundary

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principles: priority is given to official regulatory authorities, international organisations, standards organisations and publicly available regulatory materials; industry media and project experience are used only as supporting judgement.

Applicability boundary: this article supports preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.